Why Castle Biosciences' Rally Might Just Be Getting Started
Castle Biosciences (CSTL) gained over 20% after a strong Q3 performance. The stock is in Phase 8, indicating bullish momentum per Adhishthana Principles. CSTL could reach $35, starting Phase 9 before January 2026. Investors are advised to maintain bullish positions and explore accumulation opportunities. Positive momentum is expected in the upcoming Buddhi period starting December 2025.
View signal analysis